Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, announced today that Tepnel Pharma Services (Tepnel), a subsidiary of Hologic, has become an authorised Affymetrix Service Provider and has launched the Affymetrix OncoScan FFPE Service.
Tepnel’s designation as an authorised Affymetrix Service Provider reflects its commitment to customer satisfaction through processes and quality measures designed to generate high-quality data.
The Affymetrix OncoScan FFPE Assay Kit, utilising Affymetrix’s unique Molecular Inversion Probe (MIP) technology, is designed to analyse small amounts of highly degraded DNA from formalin-fixed, paraffin-embedded (FFPE) samples quickly and affordably, providing a significant step forward in solid tumor cancer analysis.
Tepnel Pharma Services uses the Affymetrix platform as part of its Molecular Genetic Services portfolio in support of biomarker discovery, assay development, assay validation and companion diagnostics development. The addition of the OncoScan technology provides Tepnel’s customer base with access to an oncology specific panel for high-quality copy number and genotype data with whole-genome coverage and high resolution in cancer genes for use with challenging FFPE samples.
David Scott, Tepnel’s Senior Director of Commercial Services said, “As a high-quality, regulatory-compliant service provider, we are pleased to receive this service certification and to add a new technology to our Molecular Genetic Services portfolio. Our commitment to working in partnership with companies such as Affymetrix provides our customers with access to a wide range of technologically advanced products and services that help them realise the requirements of their research, clinical and companion diagnostics projects. We are dedicated to providing services and products that meet the needs of today’s personalised medicines and twenty-first century healthcare.”
“The significance of copy number aberrations has now been established in a broad range of solid tumors but until recently, there has been no solution for genome-wide analysis from low input, FFPE samples,” said Padma Sundar, Marketing Director, Clinical Applications Business Unit at Affymetrix. “The OncoScan FFPE assay provides laboratories with a quick and affordable way to analyse degraded FFPE samples to correlate copy number aberrations found across the genome with outcomes data. We are delighted that Tepnel Pharma Services will be offering a service to make this capability broadly available to their customers.”
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information on Hologic please visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
About Tepnel Pharma Services:
Tepnel Pharma Services is the Contract Research Organization (CRO) group of Hologic, Inc. Tepnel specialises in the provision of pharmaceutical testing and molecular genetic services in support of drug development and companion diagnostics development. Tepnel’s pharmaceutical testing facilities are located in Manchester, England and Livingston, Scotland.
Forward-Looking Statement Disclaimer:
This Media Release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic, Inc. and our products and services. There can be no assurance these products and services will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient. Hologic disclaims any obligation to release publicly any updates or revisions to the any such statements presented herein or to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Marketing Communications Manager
Tel: + 44 (0) 161 946 2220